In this article in the Journal of Health Politics, Policy and Law, Larry Levitt examines the Affordable Care Act 10 years after it’s enactment. The article notes that the law has taken numerous blows, yet due to its policy design and the political forces it has unleashed, the law has shown remarkable resilience.
- view as grid
- view as list
Drew Altman looks at the numbers for COVID-19 treatment, and why it may soon be necessary for Congress to waive out-of-pocket costs for treatment.
In this Axios column, Drew Altman shows that the majority of supporters don’t know how Medicare-for-all works, with both positive and negative implications for support if they knew more.
In this February 2020 post for The JAMA Health Forum, Mollyann Brodie and Ashley Kirzinger examine the role health care has played in the primary election to date, what the polling data says about the issue, including Medicare-for-all and a public option, and what to expect from the issue during the rest of the 2020 election campaign.
In this Axios column, Drew Altman analyzes KFF’s tracking poll and shows that the ACA is now yesterday’s issue for Republicans. They have shifted their sights to Medicare-for-all…at least for this election season.
In this Axios column, Drew Altman analyzes data from the New Hampshire exit poll showing that support for Medicare-for-all played a role in the primary while broader support for a more moderate plan may be a signal about the general election.
In this post for The JAMA Forum, Larry Levitt examines both the Democratic candidates’ proposals and the Trump administration’s record on lowering drug prices, which remains a top issue for the public with bi-partisan support.
A data surprise? Drew Altman, in his latest Axios column, shows there is no difference between large self-insured and fully insured companies when it comes to controlling health care costs, bucking conventional wisdom.
In an Axios column, Drew Altman explains that the elimination of the Affordable Care Act’s individual mandate penalty has had little impact on how the ACA’s insurance markets are working, showing that “the marketplaces continue to function, even when ‘severed’ from the mandate penalty,” and undercutting a central argument in the lawsuit seeking to strike down the entire law.
With a questionable outlook for 2020 passage of legislation on prescription drug pricing and surprise medical bills, Drew Altman says the real action to watch in health policy is likely to be in the states.